Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA with Phase III CLL Study Data
April 08, 2014 at 08:01 AM EDT
Pharmacyclics (NASDAQ: PCYC) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug ...